156 related articles for article (PubMed ID: 27389568)
1. Lipid-based nanosystems for CD44 targeting in cancer treatment: recent significant advances, ongoing challenges and unmet needs.
Nascimento TL; Hillaireau H; Vergnaud J; Fattal E
Nanomedicine (Lond); 2016 Jul; 11(14):1865-87. PubMed ID: 27389568
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic Acid-Based pH-Sensitive Polymer-Modified Liposomes for Cell-Specific Intracellular Drug Delivery Systems.
Miyazaki M; Yuba E; Hayashi H; Harada A; Kono K
Bioconjug Chem; 2018 Jan; 29(1):44-55. PubMed ID: 29183110
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic Acid Surface Modified Liposomes Prepared via Orthogonal Aminoxy Coupling: Synthesis of Nontoxic Aminoxylipids Based on Symmetrically α-Branched Fatty Acids, Preparation of Liposomes by Microfluidic Mixing, and Targeting to Cancer Cells Expressing CD44.
Bartheldyová E; Effenberg R; Mašek J; Procházka L; Knötigová PT; Kulich P; Hubatka F; Velínská K; Zelníčková J; Zouharová D; Fojtíková M; Hrebík D; Plevka P; Mikulík R; Miller AD; Macaulay S; Zyka D; Drož L; Raška M; Ledvina M; Turánek J
Bioconjug Chem; 2018 Jul; 29(7):2343-2356. PubMed ID: 29898364
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronic acid modification of RNase A and its intracellular delivery using lipid-like nanoparticles.
Wang X; Li Y; Li Q; Neufeld CI; Pouli D; Sun S; Yang L; Deng P; Wang M; Georgakoudi I; Tang S; Xu Q
J Control Release; 2017 Oct; 263():39-45. PubMed ID: 28153764
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronate-Lipid Nanohybrids: Fruitful Harmony in Cancer Targeting.
Freag MS
Curr Pharm Des; 2017; 23(35):5283-5291. PubMed ID: 28552066
[TBL] [Abstract][Full Text] [Related]
6. Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes.
Qhattal HS; Liu X
Mol Pharm; 2011 Aug; 8(4):1233-46. PubMed ID: 21696190
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid-based drug nanocarriers as a novel drug delivery system for cancer chemotherapy: A systematic review.
Salari N; Mansouri K; Valipour E; Abam F; Jaymand M; Rasoulpoor S; Dokaneheifard S; Mohammadi M
Daru; 2021 Dec; 29(2):439-447. PubMed ID: 34499323
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid-Lipid Conjugate.
Sakurai Y; Kato A; Hida Y; Hamada J; Maishi N; Hida K; Harashima H
J Pharm Sci; 2019 Oct; 108(10):3218-3224. PubMed ID: 31229434
[TBL] [Abstract][Full Text] [Related]
9. Smart nanoparticles with a detachable outer shell for maximized synergistic antitumor efficacy of therapeutics with varying physicochemical properties.
Yin T; Liu J; Zhao Z; Dong L; Cai H; Yin L; Zhou J; Huo M
J Control Release; 2016 Dec; 243():54-68. PubMed ID: 27702595
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic Acid-Decorated Chitosan Nanoparticles for CD44-Targeted Delivery of Everolimus.
Chiesa E; Dorati R; Conti B; Modena T; Cova E; Meloni F; Genta I
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30087241
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells.
Hayward SL; Wilson CL; Kidambi S
Oncotarget; 2016 Jun; 7(23):34158-71. PubMed ID: 27120809
[TBL] [Abstract][Full Text] [Related]
12. Advances in Hyaluronic Acid-Based Drug Delivery Systems.
Jiao Y; Pang X; Zhai G
Curr Drug Targets; 2016; 17(6):720-30. PubMed ID: 26028046
[TBL] [Abstract][Full Text] [Related]
13. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer.
Karousou E; Misra S; Ghatak S; Dobra K; Götte M; Vigetti D; Passi A; Karamanos NK; Skandalis SS
Matrix Biol; 2017 May; 59():3-22. PubMed ID: 27746219
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine.
Mattheolabakis G; Milane L; Singh A; Amiji MM
J Drug Target; 2015; 23(7-8):605-18. PubMed ID: 26453158
[TBL] [Abstract][Full Text] [Related]
15. Innovative therapy of ovarian cancer based on overexpression of CD44 receptor.
Bukowska B; Marczak A
Ginekol Pol; 2015 May; 86(5):388-91. PubMed ID: 26117979
[TBL] [Abstract][Full Text] [Related]
16. Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate cancer.
Mahira S; Kommineni N; Husain GM; Khan W
Biomed Pharmacother; 2019 Feb; 110():803-817. PubMed ID: 30554119
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes.
Qhattal HS; Hye T; Alali A; Liu X
ACS Nano; 2014 Jun; 8(6):5423-40. PubMed ID: 24806526
[TBL] [Abstract][Full Text] [Related]
18. Cancer cell specific targeting of nanogels from acetylated hyaluronic acid with low molecular weight.
Park W; Kim KS; Bae BC; Kim YH; Na K
Eur J Pharm Sci; 2010 Jul; 40(4):367-75. PubMed ID: 20417709
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer.
Jeannot V; Gauche C; Mazzaferro S; Couvet M; Vanwonterghem L; Henry M; Didier C; Vollaire J; Josserand V; Coll JL; Schatz C; Lecommandoux S; Hurbin A
J Control Release; 2018 Apr; 275():117-128. PubMed ID: 29474960
[TBL] [Abstract][Full Text] [Related]
20. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.
Birzele F; Voss E; Nopora A; Honold K; Heil F; Lohmann S; Verheul H; Le Tourneau C; Delord JP; van Herpen C; Mahalingam D; Coveler AL; Meresse V; Weigand S; Runza V; Cannarile M
Clin Cancer Res; 2015 Jun; 21(12):2753-62. PubMed ID: 25762343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
